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Objective: Fenestrated and branched endovascular devices are increasingly used for complex aortic diseases, and despite the
challenging nature of these procedures, early experiences from pioneering centers have been encouraging. The objectives
of this retrospective study were to report our experience of intraoperative adverse events (IOAEs) during fenestrated and
branched stent grafting and to analyze the impact on clinical outcomes.
Methods: Consecutive patients treated with fenestrated and branched stent grafting in a tertiary vascular center between
February 2006 and October 2013 were evaluated. A prospectively maintained computerized database was scrutinized and
updated retrospectively. Intraoperative angiograms were reviewed to identify IOAEs, and adverse events were categorized
into three types: target vessel cannulation, positioning of graft components, and intraoperative access. Clinical conse-
quences of IOAEs were analyzed to ascertain whether they were responsible for death or moderate to severe postoperative
complications.
Results: During the study period, 113 consecutive elective patients underwent fenestrated or branched stent grafting.
Indications for treatment were asymptomatic complex abdominal aortic aneurysms (CAAAs, n [ 89) and thor-
acoabdominal aortic aneurysms (TAAAs, n [ 24). Stent grafts included fenestrated (n [ 79) and branched (n [ 17)
Cook stent grafts (Cook Medical, Bloomington, Ind), Ventana (Endologix, Irvine, Calif) stent grafts (n [ 9), and
fenestrated Anaconda (Vascutek Terumo, Scotland, UK) stent grafts (n [ 8). In-hospital mortality rates for the CAAA
and TAAA groups were 6.7% (6 of 89) and 12.5% (3 of 24), respectively. Twenty-eight moderate to severe complications
occurred in 21 patients (18.6%). Spinal cord ischemia was recorded in six patients, three of which resolved completely.
A total of 37 IOAEs were recorded in 34 (30.1%) patients (22 CAAAs and 12 TAAAs). Of 37 IOAEs, 15 (40.5%) resulted
in no clinical consequence in 15 patients; 17 (45.9%) were responsible for moderate to severe complications in 16 patients,
and ﬁve (13.5%) led to death in four patients. The composite end point death/nonfatal moderate to severe complication
occurred more frequently in patients with IOAEs compared with patients without IOAEs (20 of 34 vs 12 of 79;
P < .0001).
Conclusions: In this contemporary series, IOAEs were relatively frequent during branched or fenestrated stenting pro-
cedures and were often responsible for signiﬁcant complications. (J Vasc Surg 2014;60:571-8.)Fenestrated and branched endovascular aneurysm re-
pairs (FEVAR and BEVAR) have become an attractive
alternative to open repair for complex abdominal aortic an-
eurysms (CAAAs) and thoracoabdominal aortic aneurysms
(TAAAs). In many countries, these complex procedures are
still under evaluation and generally available only in tertiary
centers. In France, fenestrated and branched Cook devices
have been approved for reimbursement from the national
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://dx.doi.org/10.1016/j.jvs.2014.02.065and complications are not rare.1 Safe target vessel cannula-
tion and stenting is a concern, particularly in the presence
of stenotic ostial lesions and small or angulated target ves-
sels. Malpositioning of stent graft components can also
have devastating consequences. As delivery devices are
larger than in standard infrarenal endovascular aneurysm
repair (EVAR) and the procedure duration is generally
longer, patients are more prone to access complications.
The real incidence of those intraoperative adverse events
(IOAEs) and their impact on the postoperative course are
poorly documented.
In this retrospective study, we report the incidence of
IOAEs during fenestrated or branched stent grafting and
analyze to what extent these adverse events may inﬂuence
early postoperative outcomes.
METHODS
Study setting. Consecutive patients undergoing
FEVAR or BEVAR between February 2006 and October
2013 in a tertiary vascular unit (Henri Mondor Hospital,
Créteil) were included. Patients were treated for CAAAs
and TAAAs. CAAAs included short-necked infrarenal,571
Table I. Clinical and anatomic data
CAAA (n ¼ 89) TAAA (n ¼ 24) Overall (N ¼ 113)
Clinical data
Males 80 (90) 21 (87) 101 (89)
Age, years 73 6 9 72 6 9 73 6 9
Diabetes mellitus 17 (19) 2 (8) 19 (17)
Tobacco use in last 10 years 52 (58) 15 (62) 67 (59)
Hypertension 62 (70) 17 (71) 79 (70)
Hyperlipidemia 46 (52) 10 (42) 56 (50)
Coronary artery disease 46 (52) 7 (29) 53 (47)
Myocardial infarction 21 (24) 3 (12) 25 (22)
Congestive heart failure 22 (25) 8 (33) 30 (27)
Arrhythmia 14 (16) 3 (12) 17 (15)
Cerebrovascular disease 19 (21) 1 (4) 20 (18)
Chronic renal insufﬁciency 17 (19) 4 (17) 21 (19)
Pulmonary disease 35 (39) 9 (37) 44 (39)
Peripheral vascular disease 13 (15) 4 (17) 17 (15)
Cancer 14 (16) 5 (21) 19 (17)
Obesity 18 (20) 3 (12) 21 (19)
Anatomic data
Maximal diameter, mm 59 6 10 60 6 10 59 6 10
Type of aneurysm Short neck/juxtarenal: 63 (71)
Pararenal: 20 (22)
Suprarenal: 6 (7)
Type II: 8 (33)
Type III: 9 (37)
Type IV: 7 (29)
CAAA, Complex abdominal aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm.
Continuous data are presented as mean 6 standard deviation and categorical data as number (%).
Table II. Details of stent graft conﬁgurations
Stent graft conﬁguration No. (%)
Fenestrated stent grafts 96 (85)
One fenestration 4 (4)
Two fenestrations 43 (38)
Three fenestrations 36 (32)
Four fenestrations 13 (12)
Branched stent grafts 11 (10)
Three branches 1 (1)
Four branches 10 (9)
Stent grafts with fenestrations and branches 6 (5)
Three target vessels 1 (1)
Four target vessels 5 (4)
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rysms, considered unsuitable for conventional EVAR.
TAAAs were classiﬁed according to the Crawford classiﬁca-
tion.2 In our institution, all patients with CAAAs and TAAAs
are considered for open, hybrid, or endovascular repair in a
multidisciplinary meeting including vascular surgeons, inter-
ventional radiologists, and anesthesiologists. Demographic,
anatomic, intraoperative, and postoperative data were
recorded by means of a prospectively collected database.
Preoperative assessment and device sizing. All pa-
tients underwent a high-resolution computed tomography
scan preoperatively and before discharge. Procedure plan-
ning and device sizing were performed with a dedicated
three-dimensional vascular imaging workstation (Aquarius
WS; TeraRecon Inc, Mateo, Calif) with centerline luminal
reconstructions. The aneurysm morphology was assessed by
a vascular surgeon (M.M.) and an interventional radiologist
(H.K.), both with considerable experience with EVAR.Device designs proposed by the implanting physicians were
systematically reviewed and approved by the planning center
of the corresponding device manufacturer.
Details of procedures. Procedures were performed in
an angiography suite (Philips FD20; Philips Healthcare,
Cleveland, Ohio) in a sterile environment. An experienced
proctor physician was present during the procedure for the
ﬁrst ﬁve Cook fenestrated cases, the ﬁrst two Cook
branched cases, and the ﬁrst fenestrated Anaconda and
Ventana cases. Eight physician-modiﬁed fenestrated stent
grafts were excluded. For each device, the implantation
techniques have been described previously.3-9 Control an-
giograms were obtained once each target vessel was can-
nulated with a long sheath, after deployment of bridging
covered stents in each target vessel, and at the end of the
procedure. Each control angiogram was saved and images
were stored in a database. Technical problems and subse-
quent IOAEs were also recorded in the database.
Deﬁnitions. IOAEs were deﬁned as any intraoperative
complication or technical problem occurring during stent
graft implantation that required additional and unexpected
endovascular manipulations. IOAEs were classiﬁed in three
distinct types:
Type 1: Problems with target vessel cannulation;
Type 2: Malpositioning of one of the following graft
components: bridging stents, bifurcated component,
or iliac extensions; and
Type 3: Difﬁculty with intraoperative access.
Complications were deﬁned according to the Society
for Vascular Surgery criteria.10 Only moderate and severe
complications were reported in the current series.
Table III. Details of patients who died during the postoperative course
Gender
Age,
ASA class
Anatomic details
and expected technical
difﬁculties Stent graft Details of IOAE Cause of death
Patients who presented
with IOAE
Patient 55 M 65 years
ASA 4
Type IV TAAA
>50% stenoses of RRA,
LRA, and right CIA
Shaggy aorta
4 fenestrations, Cook RRA and LRA
cannulation failure
Graft limb occlusion
requiring bilateral
thrombectomy and
iliofemoral bypasses
Paraplegia, renal failure,
pneumonia
Patient 74 M 78 years
ASA 4
Type III TAAA
>45-degree aortic
angulation
>50% stenosis of the CT
Two accessory renal
arteries
Severe iliac tortuosity
4 visceral branches, one
additional branch for
temporary elective sac
perfusion to prevent
spinal cord ischemia,
Cook
Sizing error: additional
branch placed at the
level of overlap
between two
components
Paraplegia,
meningoencephalitis
after spinal drain
placement
Patient 80 F 71 years
ASA 4
Juxtarenal AAA
>50% stenosis of SMA
Narrowed infrarenal aorta
(<18 mm)
Short occlusion of left
CIA
Sharp angulation of aortic
bifurcation
<7.5 mm EIA
3 fenestrations,
Anaconda
Sizing error
RRA cannulation failure
and difﬁcult
cannulation of SMA
Bowel ischemia due to
SMA stent occlusion
MOSF despite splenic
artery to SMA
transposition
Patient 95 M 82 years
ASA 4
Pararenal AAA
Shaggy aorta
3 fenestrations, Cook SMA cannulation failure
requiring a bailout
chimney stent for the
SMA
Cholesterol embolism
syndrome, bowel
ischemia
SMA and CT patent on
control computed
tomography scan
Patients who had
no IOAE
Patient 30 M 76 years
ASA 4
Juxtarenal AAA
Shaggy aorta
Narrowed infrarenal aorta
(<18 mm)
4 fenestrations, Cook No IOAE Cholesterol embolism
syndrome, bowel
ischemia
SMA and CT patent on
control computed
tomography scan
Patient 39 M 82 years
ASA 3
Juxtarenal AAA
Floating thrombus in the
visceral aorta, severe
iliac tortuosity
3 fenestrations, Cook No IOAE Cholesterol embolism
syndrome, bowel
ischemia
SMA and CT patent on
control computed
tomography scan
Patient 42 M 71 years
ASA 4
Suprarenal AAA
Narrowed infrarenal aorta
(<18 mm)
3 fenestrations, aortouni-
iliac device for
narrowed aortic
bifurcation, Cook
No IOAE but long
procedure
Femorofemoral prosthetic
graft infection
Developed MOSF despite
prosthetic graft
replacement by a
venous graft
Patient 49 M 76 years
ASA 4
Juxtarenal AAA
Small (<5 mm) LRA
3 fenestrations, Cook No IOAE Pneumonia, SARS
Patient 65 M 63 years
ASA 2
Type IV TAA 4 fenestrations, Cook No IOAE Bowel ischemia,
unexplained occlusion
of SMA and CT stents
at day 1
Developed MOSF despite
successful SMA stent
thrombectomy and
colonic and bowel
resection
AAA, Aortic abdominal aneurysm; ASA, American Society of Anesthesiologists; CIA, common iliac artery; CT, celiac trunk; EIA, external iliac artery;
F, female; IOAE, intraoperative adverse event; LRA, left renal artery; M, male; MOSF, multiorgan system failure; RRA, right renal artery; SARS, severe acute
respiratory syndrome; SMA, superior mesenteric artery; TAAA, thoracoabdominal aneurysm.
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surgeon (F.C.) reviewed intraoperative and postoperative
data recorded in the prospectively maintained FEVAR or
BEVAR database and all intraoperative angiograms foreach patient to identify IOAEs. Both clinicians also partic-
ipated in the majority of the procedures.
To evaluate the clinical consequences of IOAEs
for postoperative outcome, the composite end point
Table IV. Nonfatal early postoperative moderate to
severe complications
Moderate to severe nonfatal complications
N ¼ 28 in
21 patients (18.6%)
Systemic
Renal insufﬁciency 9
Spinal cord injury 4
Complete 1
Transient 3
Stroke 1
Colonic ischemia 1
Deployment/implant-related complications
Access artery thrombosis 5
Cholesterol embolism syndrome 2
Arterial perforation 1
SMA stent occlusion 1
Access site lymphorrhea 1
Access site hematoma 2
Acute limb compartment syndrome 1
Complications related to IOAE 17
Complications unrelated to IOAE 11
IOAE, Intraoperative adverse event; SMA, superior mesenteric artery.
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mined for patients with and without IOAEs. Because this
present study focused only on short-term follow-up, endo-
leaks identiﬁed on control angiograms or on postoperative
computed tomography scans were not considered IOAEs
or complications.
RESULTS
Patient population. During the 7½ year study period,
113 consecutive elective patients underwent FEVAR or
BEVAR. No fenestrated or branched devices were
implanted to treat infected or ruptured aneurysms. All pa-
tients were deemed at high risk for open repair. Demo-
graphic and anatomic data are presented in Table I.
Device implantation. Stents implanted in this study
population were fenestrated or branched Cook (Cook
Medical, Bloomington, Ind) stents in 96 of 113 (85%),
Ventana (Endologix, Irvine, Calif) stents in 9 of 113
(8%) cases, and Anaconda (Vascutek Terumo, Scotland,
UK) stents in 8 of 113 (7%) cases. For CAAAs, there
were no speciﬁc criteria for choosing which stent to use.
Choice was made according to the surgeon’s preference.
For TAAAs, we used the Cook device. Details of stent graft
design and number of fenestrations and branches are
detailed in Table II. The mean (standard deviation) num-
ber of target vessels per patient was 2.8 6 0.8.
Clinical outcomes and IOAEs. The overall in-
hospital mortality was 8.0% (9 of 113 patients). In-
hospital mortality rates for the CAAA and TAAA groups
were 6.7% (6 of 89) and 12.5% (3 of 24), respectively
(Table III). A total of 28 moderate to severe complications
occurred in 21 (18.6%) patients (Table IV); 17 complica-
tions were related to IOAEs, and 11 occurred without any
IOAE. In patients with TAAAs, complete paraplegia
occurred in three cases (12.5%). Two other patients pre-
sented with paraparesis that resolved completely after spinal
ﬂuid drainage. In the CAAA group, one patient with a
juxtarenal aneurysm who underwent fenestrated stent
grafting with three fenestrations presented with hypo-
esthesia of both limbs that resolved completely after spinal
ﬂuid drainage.
A total of 37 IOAEs were recorded in 34 (30.1%)
patients (22 CAAAs and 12 TAAAs). Of 37 IOAEs, 15
(40.5%) resulted in no clinical consequence in 15 patients;
17 (45.9%) were responsible for moderate to severe com-
plications in 16 patients, and ﬁve (13.5%) were directly or
indirectly responsible for death in four patients. The com-
posite end point death/nonfatal moderate to severe compli-
cation occurred more frequently in patients with IOAEs
compared with patients without IOAEs (20 of 34 vs 12
of 79; P < .0001, c2 test). IOAEs occurred in 22 of 89
(25%) CAAA patients compared with 12 of 24 (50%)
TAAA patients (P ¼ .02, c2 test). IOAEs occurred in 24
of 96 patients (25%) who underwent a fenestrated stent
graft compared with 10 of 17 patients (58.9%) who under-
went a branched stent graft (P ¼ .005, c2 test). In both
those groups, difﬁculty with target vessel cannulation
(type 1 IOAE) was the most frequent (Table V). Theincidence of IOAEs was not signiﬁcantly different in pa-
tients who underwent a Cook fenestrated stent graft
compared with patients who underwent an Anaconda or
a Ventana fenestrated stent graft. The incidence of IOAE
did not change over time (Fig).
Type 1 IOAEs (problems with target vessel cannulation)
occurred in 22 of 113 cases (19.4%), resulting in death
(n ¼ 3) or moderate to severe complication (n ¼ 10) in
13 patients (59.1%). They led to target vessel loss in ﬁve
cases (22.7%). Details of type 1 IOAEs, intraoperative man-
agement, and related outcomes are given in Table VI.
Type 2 IOAEs (malpositioning of one of the graft
components) occurred in 5 of 113 cases (4.4%), resulting
in death or complication in two patients (Table VII).
Type 3 IOAEs (related to access site problems)
occurred in 10 of 113 patients (8.8%), leading to early
postoperative death in one patient and moderate to severe
complications in another six patients (Table VIII).
DISCUSSION
The utility of fenestrated and branched devices for the
treatment of CAAAs and TAAAs has gained widespread
acceptance, with several large series conﬁrming satisfactory
early and midterm results.5,11-15 In a recent systematic re-
view of juxtarenal abdominal aortic aneurysms treated by
FEVAR,16 368 FEVAR cases from eight cohort studies
were evaluated. The reported 30-day mortality was 1.4%,
and the incidence of permanent renal dialysis was 1.4%.
Data from national registries and from high-volume centers
have provided similar results, with 30-day mortality rates
varying from 2% to 4%.13,14,17 In expert hands, endovascu-
lar repair of TAAA with FEVAR or BEVAR has been asso-
ciated with encouraging short-term results, with 30-day
mortality ranging from 5% to 12% and spinal cord ischemia
from 3% to 17%.4,12,18-20
Table V. Incidence of intraoperative adverse events (IOAEs) according to the type of stent graft
Patients presenting
with IOAE
F grafts, B grafts, P values,a
Cook F
(n ¼ 79)
Ventana F
(n ¼ 9)
Anaconda F
(n ¼ 8)
All F grafts
(n ¼ 96)
Cook B
(n ¼ 17)
Cook F vs
Anaconda F
Cook F vs
Ventana F
Anaconda F
vs Ventana F
All F grafts
vs B Cook
Type 1 IOAE 10 (12.7) 2 (22.2) 2 (25) 14 (14.6) 8 (47.1) .3 .6 1 .002
Type 2 IOAE 4 (5.1) 0 0 4 (4.2) 1 (5.9) 1 1 1 .6
Type 3 IOAE 8 (10.1) 0 0 8 (8.3) 2 (11.8) 1 1 1 .7
Any type of IOAE 20 (25.3)b 2 (22.2) 2 (25.0) 24b (25.0) 10 (58.9)c 1 1 1 .005
B, Branched or branched and fenestrated grafts; F, fenestrated; type 1 IOAE, problems with target vessel cannulation; type 2 IOAE,malpositioning of one of the
nonfenestrated graft components (bridging stents, bifurcated component, or iliac extensions); type 3 IOAE, difﬁculty with intraoperative access.
Data are presented as number (%).
aFisher exact test or c2 test.
bTwo patients presented with two types of IOAE.
cOne patient presented with two types of IOAE.
Fig. Evolution of intraoperative adverse event (IOAE) incidence
over time. F/BEVAR, Fenestrated and branched endovascular
aneurysm repair; TAAA, thoracoabdominal aortic aneurysm.
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tients and 12.5% for TAAA patients, our results do not
compare favorably with previously published data. Several
reasons might explain this observation. In contrast with
pioneering series, in which one physician performed the
majority of the cases, two vascular surgeons in our institu-
tion performed fenestrated and branched procedures as the
ﬁrst operator, although a highly experienced interventional
radiologist (H.K.) was present during almost all proce-
dures. This, combined with the fact that three different
types of device were used, might have contributed to
IOAEs in some patients. However, more than a simple
learning curve of technical skills, one could argue that
our results are mainly due to suboptimal patient selection.
On review of the mortalities in this series, all patients had
challenging aneurysm morphology or signiﬁcant comor-
bidity (American Society of Anesthesiologists class 4).
Four patients had “shaggy” aortas with ﬂoating thrombus,
resulting in fatal embolic complications. As FEVAR and
BEVAR are being increasingly used and disseminated, theresults of our initial experience conﬁrm that they remain
complex procedures that need to be centralized in high-
volume centers. They also raise the question of whether
encouraging results of initial series can be reproduced in
the “real world,” knowing these series came from a very
few pioneering expert centers and included highly selected
patients.
Type 1 IOAEs (problems with target vessel cannula-
tion) were the most frequent in our experience (n ¼ 22).
Target vessel occlusions and dissections occurred in 11
cases and were mainly due to target vessel injury or
thrombus formation in the long 7F sheaths. Even if most
of them could be rescued with additional bailout endovas-
cular maneuvers and without permanent damaging conse-
quences for the patient (Table VI), they are considered
avoidable. Thrombus formation in the long 7F sheaths
may also have been avoided by more frequent ﬂushing.
Cannulation failure was relatively rare (n ¼ 4) but had
devastating consequences for the patient, leading directly
or indirectly to severe complications or death (Table VI).
This was mainly due to sizing errors, malpositioning of
the fenestrated component, or difﬁcult anatomy and
occurred predominantly at the beginning of our experience.
Type 2 IOAEs (malpositioning of bridging stents,
bifurcated component, or iliac extensions) are also consid-
ered avoidable technical errors. In our series, they occurred
in ﬁve cases. In one patient with a type II TAAA, a sac
perfusion branch had to be covered as it was inadvertently
located at an overlap zone. The patient subsequently died
of meningoencephalitis after spinal drain placement for
paraplegia, although the use of sac perfusion branches to
reduce paraplegia risk remains controversial. With the
exception of one endovascular reintervention, all remaining
IOAEs relating to graft malpositioning were managed suc-
cessfully without harm to the patient.
FEVAR and BEVAR procedures are frequently long,
require large-diameter introducer sheaths, and are prone
to access vessel complications. In this series, intraoperative
access site problems (type 3 IOAEs) occurred in 10
patients (8.8%), leading to moderate or severe complica-
tions in seven cases. In our current practice, we use a
Table VI. Details of type 1 intraoperative adverse events (IOAEs) (problems with target vessel cannulation) and clinical
consequences
Type of IOAE Number of events (n ¼ 22) Intraoperative treatment
Consequences for target
vessel and related outcomes Clinical outcomes
RA occlusion or
dissection
10 Thrombolysis: 4
Thrombolysis and
thromboaspiration: 2
Thrombolysis and
additional stent
placement: 2
Additional stent
placement: 2
Remained patent: 8 Dialysis: 1
Permanently reduced
renal function: 1
Temporarily reduced
renal function: 2
No impact on renal
function: 4
Target vessel lost: 2 Permanently reduced
renal function: 1
Temporarily reduced
renal function: 1
SMA dissection 1 Additional sent placement Remained patent Asymptomatic
RA cannulation failure 3 d Target vessel lost: 3 Death: 2
Permanent reduced renal
function: 1
SMA cannulation failure 1 Bailout chimney stent Remained patent Death
RA rupture 2 Additional stent
placement: 1
Remained patent Asymptomatic
Distal coil embolization: 1 Remained patent Temporarily reduced
renal function: 1
Other difﬁculties during
target vessel
cannulation
Difﬁcult cannulation of
both RAs
Mispositioning of a
scallop dedicated to
SMA
Scallop deployed in
posterior position
Two stents for two right
RAs in the same
fenestration
RRA stented through a
scallop dedicated to
SMA
d
d
d
Endovascular occlusion
of the nonstented
fenestration
SMA stented through
the same scallop
Remained patent
Partial covering of the
SMA
Remained patent
Remained patent
Remained patent
Long operation, acute
compartment
syndrome requiring
fasciotomies
Reintervention for SMA
stenting
Asymptomatic
Asymptomatic
Asymptomatic
RA, Renal artery; RRA, right renal artery; SMA, superior mesenteric artery.
Table VII. Details of type 2 intraoperative adverse events (IOAEs) (malpositioning of one of the nonfenestrated graft
components) and clinical consequences
Details of graft component malpositioning Clinical outcomes
Sizing error leading to malpositioning and coverage of an additional
branch for temporary elective sac perfusion to prevent spinal cord
ischemia
Paraplegia, meningoencephalitis after spinal drain placement, death
Inadequate positioning of SMA stent, long portion remaining in the
aortic lumen
Early occlusion of SMA stent, bowel ischemia
Successful endovascular stent removal, placement of another
covered stent
Right graft limb disconnection requiring placement of an additional
graft limb
None
Unintentional coverage of the LIIA None
Unintentional coverage of the RIIA None
LIIA, Left internal iliac artery; RIIA, right internal iliac artery; SMA, superior mesenteric artery.
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Because of the increased risk of access complications during
FEVAR and BEVAR procedures, we still favor surgical cut-
down of femoral arteries.
Caution should be taken in interpreting the results of
this series as the deﬁnition of CAAA is broad, includingshort neck, juxtarenal, pararenal, and suprarenal aneu-
rysms. Consequently, there was considerable heterogeneity
in complexity of aneurysm morphology and difﬁculty of
procedures, which varied from stents with two fenestra-
tions to challenging branched stent grafting for type II
TAAAs in high-risk patients. Despite these limits, this study
Table VIII. Details of type 3 intraoperative adverse events (IOAEs) (access site problems) and clinical consequences
Type of access site problem (n ¼ 10) Intraoperative treatment Clinical outcomes
Iliac or graft limb occlusion: 5 Thrombectomy: 3 Asymptomatic: 2
Reintervention for acute leg ischemia needing
femorofemoral crossover bypass: 1
Thrombectomy and additional stent: 1 Asymptomatic: 1
Thrombectomy and iliofemoral bypass: 1 Reintervention for fasciotomies, death: 1
Common femoral artery iatrogenic
occlusive lesion: 4
None: unnoticed during the procedure Reintervention for acute leg ischemia: 4
Iliac injury: 1 None: unnoticed during the procedure Flank hematoma, reintervention for coil
embolization of the circumﬂex iliac artery
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IOAEs during FEVAR and BEVAR procedures are not
rare, particularly with difﬁcult aneurysm morphology. It
is likely that continuous improvements in endovascular
and imaging technologies will improve the safety of com-
plex endovascular aortic procedures. Development of lower
proﬁle stent grafts and bridging stents, with better visibility
and repositionability, will probably play a key role in
reducing IOAEs. New tools for improved catheter naviga-
tion, such as robotic navigation,21 may also facilitate target
vessel cannulation. Although few data exist, fusion of im-
ages may be useful to reduce doses of contrast material
and radiation.22
CONCLUSIONS
In our series, IOAEs during branched and fenestrated
stent grafting were frequent, occurring in 25% of patients
with CAAAs and 50% of patients with TAAAs. As branched
and fenestrated devices are being increasingly used and
disseminated in vascular centers, additional studies are
needed to determine if the encouraging results from pio-
neering expert centers can be reproduced in “real-life”
practice.
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trated/branched aortic endografting. J Vasc Surg 2011;53:583-90.Submitted Aug 12, 2013; accepted Feb 23, 2014.INVITED COMMENTARYTimothy A. Resch, MD, PhD, Malmö, SwedenThe report by Dr Cochennec highlights some very signiﬁcant
issues related to the practice and dissemination of complex aortic
procedures.
The authors present 113 cases performed during a period of
7 years, which equates to fewer than 20 cases per annum divided
among four operators using three endovascular devices. Previ-
ous studies have shown a link between surgeon as well as center
volumes and outcomes.1 Complex aneurysms represent a small
proportion of all aneurysms treated, and it is difﬁcult, even in
large vascular centers, to achieve volumes large enough to
reap the beneﬁts of truly high volumes. In contrast to “simpler”
aortic procedures, treatment of complex aneurysms is not only
a question of individual operator experience and skill, but it
places signiﬁcant demands on the supporting structure of the
center.
Preoperative planning of complex cases is paramount for suc-
cess. Detailed anatomic analysis as well as extensive speciﬁc device
knowledge is needed. The learning curve is signiﬁcantly longer
than for infrarenal endovascular aneurysm repair. This indicates
that it is better to use a single device and to learn it well rather
than to stray between different devices, trying to take advantage
of individual stent graft beneﬁts.
Certain morphologic features need to be speciﬁcally addressed.
(1) A “shaggy” aorta is a risk factor for embolic events and poor
outcome.2 (2) Poor access can lead to difﬁculties in orienting the
device, leading to target vessel loss, resulting in end-organ dysfunc-
tion. Very long procedures can lead to compartment syndrome as
well as a systemic reperfusion injury causing severe physiologicinstability and multiorgan failure in the immediate postoperative
phase.3
Patients with complex aneurysmal disease often carry signiﬁ-
cant comorbidities and generally have a much lower tolerance
for perioperative and postoperative complications, which is clearly
seen in the current study with signiﬁcant morbidity and mortality.
This furthermore emphasizes the need for appropriate patient se-
lection, workup, and optimization before surgery as well as exten-
sive involvement of anesthetic and intensive care expertise in the
preoperative, perioperative, and postoperative period. This can
most likely be achieved only in very select high-volume centers
dedicated to treatment of complex aortic disease.
I thank the authors for their honest reporting and for high-
lighting the issues in dealing with complex endovascular aortic
procedures.
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